Update on the prevalence and spread of macrolide- and lincosamide-resistant staphylococcal and streptococcal species

DiPersio, Joseph R.; DiPersio, Linda P.

doi:10.1097/01.revmedmi.0000174306.26027.e3

Cited by 6 publications

(5 citation statements)

References 56 publications

(64 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, these bacteria may pose a considerable threat to public health because of their increasing antimicrobial resistance. Accordingly, resistance to MLS B antibiotics in Gram‐positive cocci colonizing humans is now recognized to be a serious problem that may negatively affect clinical outcomes (Lim et al., 2002; DiPersio and DiPersio, 2005). It is therefore important to identify potential sources of the MLS B ‐resistant bacteria.…”

Section: Discussionmentioning

confidence: 99%

Distribution, Characterization and Genetic Bases of Erythromycin Resistance in Staphylococci and Enterococci Originating from Livestock

Jaglič

Vlkova

Bardoň

et al. 2011

Zoonoses and Public Health

View full text Add to dashboard Cite

The occurrence of staphylococci and enterococci expressing increased resistance to erythromycin (ERY) and, in particular, to macrolide-lincosamide-streptogramin B (MLS(B) ) antibiotics was investigated in dairy cattle, pigs and turkeys. Three hundred rectal (cloacal) swabs of each animal species were examined. A total of 120 and 71 staphylococci and enterococci, respectively, with increased resistance to ERY were identified. These were most frequent in turkeys (42.3% of positive animals), followed by pigs and dairy cattle (6.7% and 6.0% of positive animals, respectively). Similarly, MLS(B) -resistant isolates colonized predominantly turkeys (29.7% of animals), while their occurrence in pigs and dairy cattle was only sporadic (0.8% of animals). At least one of the erm genes encoding for MLS(B) resistance was found in 56.7% and 69.0% of staphylococci and enterococci, respectively. The erm(C) gene prevailed in staphylococci while the erm(B) gene was predominant in enterococci. Macrolide efflux genes msr(A) and msr(C) were also frequent in staphylococci and enterococci, respectively. Macrolide inactivation gene mph(C) occurred mainly in staphylococci. In staphylococci, methicillin resistance was rarely detected (7.5% of isolates), but resistance to telithromycin (ketolides) was frequent in both staphylococci and enterococci (89.2% and 47.9% of isolates, respectively). This study showed that turkeys represent an important source of ERY (MLS(B) )-resistant cocci. In addition, resistance to ketolides was also frequent.

show abstract

Section: Discussionmentioning

confidence: 99%

Distribution, Characterization and Genetic Bases of Erythromycin Resistance in Staphylococci and Enterococci Originating from Livestock

Jaglič

Vlkova

Bardoň

et al. 2011

Zoonoses and Public Health

View full text Add to dashboard Cite

show abstract

“…However, Kim et al (2004) while analysing the presence of resistance to MLSb group in Staphylococcus aureus found out that 97% of MRSA (Meticillin-Resistant Staphylococcus aureus) showed resistance to at least one of the antibiotics of this group. Epidemiologically, the crossed-resistance among these 3 classes of antimicrobials is very important Dipersio and Dipersio (2005) once they are largely used in Veterinary Medicine taking to the increase of resistance of animal origin.…”

Section: Discussionmentioning

confidence: 99%

Antimicrobial Resistance in Bacterial Pathogens of Canine Otitis

Sfaciotte¹,

Bordin²,

Vignoto³

et al. 2015

American Journal of Animal and Veterinary Sciences

View full text Add to dashboard Cite

Abstract:Otitis is one of the most frequent infections in dogs. This is attributed to the misuse of drugs enabling generation of multi-resistant micro-organisms. The emergence of multiresistant bacterial strains in veterinary medicine is a reality that must be studied and evaluated by the professionals. The objective of this study was to isolate and evaluate the antimicrobial susceptibility of bacterial pathogens of otitis in dogs. Otologic swabs were collected from 36 dogs with clinical otitis. 41 bacterial strains were isolated and antimicrobial susceptibility tests were performed by disk diffusion method with 34 antimicrobial agents. Presence of the resistance gene mecA of Staphylococcus was examined for 22 strains of staphylococci by PCR. A total of 1108 ratings antimicrobial agents were performed. The percentage of drug resistance was 34.66% (n = 384) of the assessments with partial or total resistance. Major bacterial pathogens were Staphylococcus spp. (65.85%), Pseudomonas spp. (12.19%) and Enterobacteria species (19.51%). 53.66% of the isolates were considered multiresistant. Antimicrobial agents considered most resistant in the strains studied were penicillin (75.00%), tetracyclin (50.00%), amoxicillin (48.78%), trimethoprimsulfamethoxazole (46.15%), clindamycin and rifampicin (43.24%). 11 strains were phenotypically characterized as MRS, 4 genotypically as MRS, 2 as MLSB-MRS and 2 as gram negative ESBL-producing.

show abstract

“…19 This led to the clinical development of 1 in hematopoietic stem cell mobilization and the subsequent U.S. approval of plerixafor (1) in 2008 for use in combination with granulocyte colonystimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). [20][21][22] In parallel we also discovered and developed a small-molecule, orally bioavailable CXCR4 antagonist (AMD070) (2) [23][24][25] (Figure 1) that was shown to be a potent inhibitor of T-tropic (X4) HIV-1 replication. 26 In a dose range finding study in healthy volunteers it was demonstrated that at doses ranging from 50 to 400 mg 2 is safe, well tolerated, and orally bioavailable.…”

Section: Introductionmentioning

confidence: 99%

Discovery of Novel Small Molecule Orally Bioavailable C−X−C Chemokine Receptor 4 Antagonists That Are Potent Inhibitors of T-Tropic (X4) HIV-1 Replication

Skerlj¹,

Bridger²,

Kaller³

et al. 2010

J. Med. Chem.

100

View full text Add to dashboard Cite

The redesign of azamacrocyclic CXCR4 chemokine receptor antagonists resulted in the discovery of novel, small molecule, orally bioavailable compounds that retained T-tropic (CXCR4 using, X4) anti-HIV-1 activity. A structure-activity relationship (SAR) was determined on the basis of the inhibition of replication of X4 HIV-1 NL4.3 in MT-4 cells. As a result of lead optimization, we identified (S)-N'-((1H-benzo[d]imidazol-2-yl)methyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine (AMD070) 2 as a potent and selective antagonist of CXCR4 with an IC(50) value of 13 nM in a CXCR4 125I-SDF inhibition binding assay. Compound 2 inhibited the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC(50) of 2 and 26 nM, respectively, while remaining noncytotoxic to cells at concentrations exceeding 23 microM. The pharmacokinetics of 2 was evaluated in rat and dog, and good oral bioavailability was observed in both species. This compound represents the first small molecule orally bioavailable CXCR4 antagonist that was developed for the treatment of HIV-1 infection.

show abstract

Update on the prevalence and spread of macrolide- and lincosamide-resistant staphylococcal and streptococcal species

Cited by 6 publications

References 56 publications

Distribution, Characterization and Genetic Bases of Erythromycin Resistance in Staphylococci and Enterococci Originating from Livestock

Distribution, Characterization and Genetic Bases of Erythromycin Resistance in Staphylococci and Enterococci Originating from Livestock

Antimicrobial Resistance in Bacterial Pathogens of Canine Otitis

Discovery of Novel Small Molecule Orally Bioavailable C−X−C Chemokine Receptor 4 Antagonists That Are Potent Inhibitors of T-Tropic (X4) HIV-1 Replication

Contact Info

Product

Resources

About